176 related articles for article (PubMed ID: 38300709)
1. The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
Wu M; Hanly A; Gibson F; Fisher R; Rogers S; Park K; Zuger A; Kuang K; Kalin JH; Nocco S; Cole M; Xiao A; Agus F; Labadorf A; Beck S; Collard M; Cole PA; Alani RM
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38300709
[TBL] [Abstract][Full Text] [Related]
2. p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells.
Pietrobono S; De Paolo R; Mangiameli D; Marranci A; Battisti I; Franchin C; Arrigoni G; Melisi D; Poliseno L; Stecca B
J Biol Chem; 2022 Sep; 298(9):102353. PubMed ID: 35944584
[TBL] [Abstract][Full Text] [Related]
3. miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment.
Liu S; Tetzlaff MT; Wang T; Yang R; Xie L; Zhang G; Krepler C; Xiao M; Beqiri M; Xu W; Karakousis G; Schuchter L; Amaravadi RK; Xu W; Wei Z; Herlyn M; Yao Y; Zhang L; Wang Y; Zhang L; Xu X
Pigment Cell Melanoma Res; 2015 Jul; 28(4):431-41. PubMed ID: 25903073
[TBL] [Abstract][Full Text] [Related]
4. The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma.
Paris A; Tardif N; Baietti FM; Berra C; Leclair HM; Leucci E; Galibert MD; Corre S
EMBO Mol Med; 2022 Dec; 14(12):e15677. PubMed ID: 36305167
[TBL] [Abstract][Full Text] [Related]
5. Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.
Singh MK; Altameemi S; Lares M; Newton MA; Setaluri V
Sci Rep; 2022 Aug; 12(1):14395. PubMed ID: 35999349
[TBL] [Abstract][Full Text] [Related]
6. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.
Wang J; Huang SK; Marzese DM; Hsu SC; Kawas NP; Chong KK; Long GV; Menzies AM; Scolyer RA; Izraely S; Sagi-Assif O; Witz IP; Hoon DSB
J Invest Dermatol; 2015 Feb; 135(2):532-541. PubMed ID: 25243790
[TBL] [Abstract][Full Text] [Related]
8. Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors.
Khamari R; Trinh A; Gabert PE; Corazao-Rozas P; Riveros-Cruz S; Balayssac S; Malet-Martino M; Dekiouk S; Joncquel Chevalier Curt M; Maboudou P; Garçon G; Ravasi L; Guerreschi P; Mortier L; Quesnel B; Marchetti P; Kluza J
Cell Death Dis; 2018 Feb; 9(3):325. PubMed ID: 29487283
[TBL] [Abstract][Full Text] [Related]
9. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
[TBL] [Abstract][Full Text] [Related]
10. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
11. BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors.
Misek SA; Foda BM; Dexheimer TS; Akram M; Conrad SE; Schmidt JC; Neubig RR; Gallo KA
Front Oncol; 2022; 12():766794. PubMed ID: 35444937
[TBL] [Abstract][Full Text] [Related]
12. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
Jandova J; Wondrak GT
J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Misek SA; Newbury PA; Chekalin E; Paithankar S; Doseff AI; Chen B; Gallo KA; Neubig RR
Mol Pharmacol; 2022 Jan; 101(1):1-12. PubMed ID: 34732527
[TBL] [Abstract][Full Text] [Related]
15. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
16. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.
Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of HMGCoA reductase and mitochondrial complex I induces tumor regression of BRAF inhibitor-resistant melanomas.
de Groot E; Varghese S; Tan L; Knighton B; Sobieski M; Nguyen N; Park YS; Powell R; Lorenzi PL; Zheng B; Stephan C; Gopal YNV
Cancer Metab; 2022 Feb; 10(1):6. PubMed ID: 35193687
[TBL] [Abstract][Full Text] [Related]
18. Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.
Steinberg SM; Shabaneh TB; Zhang P; Martyanov V; Li Z; Malik BT; Wood TA; Boni A; Molodtsov A; Angeles CV; Curiel TJ; Whitfield ML; Turk MJ
Cancer Res; 2017 Apr; 77(7):1599-1610. PubMed ID: 28202513
[TBL] [Abstract][Full Text] [Related]
19. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
Shen CH; Kim SH; Trousil S; Frederick DT; Piris A; Yuan P; Cai L; Gu L; Li M; Lee JH; Mitra D; Fisher DE; Sullivan RJ; Flaherty KT; Zheng B
Nat Med; 2016 Sep; 22(9):1056-61. PubMed ID: 27500726
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
Gallagher SJ; Gunatilake D; Beaumont KA; Sharp DM; Tiffen JC; Heinemann A; Weninger W; Haass NK; Wilmott JS; Madore J; Ferguson PM; Rizos H; Hersey P
Int J Cancer; 2018 May; 142(9):1926-1937. PubMed ID: 29210065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]